|
|
| April 11-13, 2012 | Grand Hyatt New York | New York, NY |
|
|
|
2012’s exciting new topics include:
- Dealmakers’ and Executive Compensation: Aligning Risk, Rewards and Shareholders’ Interests
- Debate: The Runners and Riders in the Race for the Next Blockbuster
- More from Less: Optimizing the R&D Budget
- Creative Deal Structures: 2010/2011 Winners
- Outlicensing: Stepping Stone or Exit?
| Featured Speakers Include: |
|
| |
 |
Keynote Fireside Chat |
 |
Keynote Fireside Chat |
 |
George S. Golumbeski, Ph.D.
SVP, Business Development
Celgene Corporation |
|
Jay Galeota
President of Hospital
and Specialty Care
Merck & Co. |
Freda C. Lewis-Hall, M.D., FAPA
Executive Vice President, Chief Medical Officer
Pfizer |
|
|
|
| |
 |
Dr. Jeffrey Jonas
SVP Research & Development
Speciality Pharmaceuticals & Regenerative Medicine
Shire plc |
 |
Ron Laufer
Senior Managing Director
MedImmune Ventures
AstraZeneca |
 |
Anthony J. Coyle, Ph.D.
VP and CSO, Centers for Therapeutic Innovation (CTI)
Pfizer, Inc. |
|
|
|
|
| |
 |
Colin Goddard
Executive Chairman
Coferon, Inc. |
 |
Julian Adams, Ph.D.
President, Research and Development
Infinity Pharmaceuticals |
 |
Iain Dukes
Vice President, External Research and Development
Amgen |
|
|
|
|
|
It is becoming increasingly difficult to identify and attract novel and potentially profitable products from among the usual suspects of Cardiovascular, Oncology, Immunology and CNS. The “low-hanging fruit” in these therapeutic fields has been largely plucked, and competition for the other assets is fierce.
- So where should companies be looking next?
- Which fields have the potential to provide big wins on the back of intelligent bets?
- And how do you measure and compensate the executives placing these bets?
- Will new technologies be the drivers of commercial success, or can creative marketing strategies continue to create blockbusters from incremental improvements in treatment?
- Will the deep cuts in-house R&D being made by the largest companies be accompanied by an improvement in productivity, or will partnering become even more critical to success?
- Will investment in new therapeutic areas result in products with sufficient revenues to drive earnings growth?
The 9th Annual Pharmaceutical Strategic Outlook (PSO) conference is an in-depth analysis on the top issues affecting the industry, creating a dynamic three days of networking and discussion. The conference offers a personal and interactive setting with in-depth on-stage interviews, panels, one-on-one partnering meetings and company presentations by carefully selected biotech companies.
Senior level business development and licensing executives from small to large pharmaceutical and biotechnology companies attend PSO to meet their current and potential strategic partners as well as hear from industry stakeholders and key thought leaders who’ll share practical advice and strategies on how to structure successful deals.
PSO 2012 will include thought-provoking discussions of the strategies employed by companies who have defied conventional wisdom to place obscure bets. And won.
Past Attending Companies - Testimonials
-
Cerenis Therapeutics SA
-
Idera Pharmaceuticals, Inc.
-
Aptalis Pharmaceutical Technologies
-
Cytokinetics Inc.
-
Liquidia
-
Epizyme
-
Excelimmune, Inc.
-
Veloxis Pharmaceuticals
-
Anaptysbio Inc.
-
Altheus
-
Axios Biosciences
-
MolMed
-
GeoVax
-
May 30-June 2, 2012
Paris, France
-
September 17-19, 2012
New York, NY - USA
-
September 24-26, 2012
Shanghai, China
Browser Compatibility
Add to Outlook Calendar
STAY CONNECTED
to the PSO event on
 |
| Important Partnering Deadlines |
Last Chance for Early Bird-Rate 1 (SAVE $400) |
2/3/2012 |
Last Chance for Early Bird-Rate 2 (SAVE $200) |
3/23/2011 |
Partnering Opens (start scheduling meetings) |
3/21/2012 |
Attendee/Company Profile Due |
3/21/2011 |
Last Chance for Discounted Rooms (rooms may sell out before this date) |
3/23/2011 |
| Click Here to view full pricing schedule. |
Who will you meet?
- • C-Level
- • Business Development
- • Strategic Alliances
- • Licensing
- • Strategic Planning
- • Corporate Development
- • R&D
- • M&A
- • Transactions
- • Decision Support
- • Market Access
- • Global Discovery Alliances
- • Financial and Strategic Planning
- • Healthcare Venture Capital/Analysts
- • Clinical Development
- • Alliance Management
- • Portfolio Management
- • Technology Transfer/Academia
- • Intellectual Property
- • Venture Philanthropy Orgs
- • Equity Research
- • Private Equity
Past Attending Companies >>
Testimonials >>
Benefits of attending
- • Meet your potential partner and find out how to approach them
- • Benchmark your dealmaking against the best and the brightest
- • Learn the deal values and deal specifics that let you calibrate deal-making metrics
- • Get key trend analysis on new business models, deal structures and deal failures
- • Maximize your strategic alliance opportunities by meeting business development leaders who’ll share practical advice and strategies on how to structure successful deals
- • Walk away with practical, real-life lessons from some of the most experienced dealmakers in the industry on how they evaluate opportunities and risk
About partnering
Why Use Windhover Conferences Partnering Software?
- • Identify attendees to choose potential partners.
- • Search database of partnering/investing opportunities (including deal history and related articles).
- • Communicate and pre-schedule as many meetings as you wish with fellow attendees.
- • Showcase your company's innovative technology and investment/partnering interests.
More Info >>
Follow us on:
|
|